Surotomycin is both bactericidal against Clostridium difficile and more potent than vancomycin in vitro. Surotomycin stays at the site of infection in the bowel, with minimal systemic absorption and it does not interfere with normal bowel flora. –
Additionally, in February 2013 – in the news: The company received from the FDA notification that Cubist`s antibiotic candidates, ceftolozane/tazobactam and surotomycin, have been granted Fast Track status in their previously granted QIDP indications, Complicated Intra-Abdominal Infections (cIAI) and Clostridium difficile-Associated Diarrhea (CDAD) respectively.
As of December 6, 2012; Pharma Research Views reported the announcement from Cubist Pharmaceuticals, Inc. that the “FDA designated the company’s Phase III antibiotic candidate, CB-315 (surotomycin), as qualified infectious disease products (QIDP).” Furthermore; “These incentives are provided under the Generating Antibiotic Incentives Now Act (GAIN Act), which received strong bipartisan support in Congress and was signed into law by President Obama in July 2012 as part of the FDA Safety and Innovation Act (FDASIA), the fifth authorization of the Prescription Drug User Fee Act. CB-315 is currently being investigated in Phase III trials as an oral therapy for Clostridium difficile-associated diarrhea, or CDAD.”
Cubist Pharm. Fact Sheet re: Surotomycin (CB-315) http://www.cubist.com/downloads/CB-315_surotomycin_13013.pdf